Literature DB >> 23535446

Early neurodevelopmental assessment in Duchenne muscular dystrophy.

Marika Pane1, Roberta Scalise, Angela Berardinelli, Grazia D'Angelo, Valeria Ricotti, Paolo Alfieri, Isabella Moroni, Louise Hartley, Maria Carmela Pera, Giovanni Baranello, Michela Catteruccia, Tiziana Casalino, Domenico M Romeo, Alessandra Graziano, Claudia Gandioli, Flaviana Bianco, Elena Stacy Mazzone, Maria Elena Lombardo, Mariacristina Scoto, Serena Sivo, Concetta Palermo, Francesca Gualandi, Maria Pia Sormani, Alessandra Ferlini, Enrico Bertini, Francesco Muntoni, Eugenio Mercuri.   

Abstract

The aim of this study was to assess neurodevelopmental profile in young boys affected by Duchenne muscular dystrophy and to establish the correlation between neurodevelopmental findings, and the type and site of mutations. A structured neurodevelopmental assessment (Griffiths Scale of Mental Development) was performed in 81 DMD boys before the age of four years (range: 7-47 months). The mean total DQ was 87 (SD 15.3). Borderline DQ (between 70 and 84) was found in 32% and DQ below 70 in 12.3% of the patients. Children with mutations upstream or in exon 44 had higher DQ than those with mutations downstream exon 44 which are associated with involvement of dystrophin isoforms expressed at high levels in brain. The difference was significant for total and individual subscale DQ with the exception of the locomotor subscale. Items, such as ability to run fast, or getting up from the floor consistently failed in all children, irrespective of the age or of the site of mutation. Our results help to understand the possible different mechanisms underlying the various aspects of neurodevelopmental delay, suggesting that the involvement of brain dystrophin isoforms may cause a delay in the maturation of coordination and dexterity.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23535446     DOI: 10.1016/j.nmd.2013.02.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  21 in total

1.  Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.

Authors:  Jacob J Gissy; Teresa Johnson; Deborah J Fox; Anil Kumar; Emma Ciafaloni; Anthonie J van Essen; Holly L Peay; Ann Martin; Ann Lucas; Richard S Finkel
Journal:  Neuromuscul Disord       Date:  2017-07-21       Impact factor: 4.296

2.  Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin.

Authors:  Gianna Móes Albuquerque-Pontes; Heliodora Leão Casalechi; Shaiane Silva Tomazoni; Andrey Jorge Serra; Cheila de Sousa Bacelar Ferreira; Rodrigo Barbosa de Oliveira Brito; Brunno Lemes de Melo; Adriane Aver Vanin; Kadma Karênina Damasceno Soares Monteiro; Humberto Dellê; Lucio Frigo; Rodrigo Labat Marcos; Paulo de Tarso Camillo de Carvalho; Ernesto Cesar Pinto Leal-Junior
Journal:  Lasers Med Sci       Date:  2017-12-05       Impact factor: 3.161

Review 3.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

4.  Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Kristin Caspers Conway; Katherine D Mathews; Pangaja Paramsothy; Joyce Oleszek; Christina Trout; Ying Zhang; Paul A Romitti
Journal:  J Dev Behav Pediatr       Date:  2015 Jul-Aug       Impact factor: 2.225

5.  Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system.

Authors:  Valeria Ricotti; Herbert Jägle; Maria Theodorou; Anthony T Moore; Francesco Muntoni; Dorothy A Thompson
Journal:  Eur J Hum Genet       Date:  2015-06-17       Impact factor: 4.246

6.  Descriptive Phenotype of Obsessive Compulsive Symptoms in Males With Duchenne Muscular Dystrophy.

Authors:  Angela J Lee; Edward T Buckingham; Aaron J Kauer; Katherine D Mathews
Journal:  J Child Neurol       Date:  2018-05-20       Impact factor: 1.987

7.  Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.

Authors:  Umar Burki; Jonathan Keane; Alison Blain; Liz O'Donovan; Michael John Gait; Steven H Laval; Volker Straub
Journal:  Nucleic Acid Ther       Date:  2015-07-15       Impact factor: 5.486

8.  204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands.

Authors:  Alessandra Ferlini; Kevin M Flanigan; Hanns Lochmuller; Francesco Muntoni; Peter A C 't Hoen; Elizabeth McNally
Journal:  Neuromuscul Disord       Date:  2014-09-11       Impact factor: 4.296

9.  One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development.

Authors:  Anne M Connolly; Julaine M Florence; Mary M Cradock; Michelle Eagle; Kevin M Flanigan; Craig M McDonald; Peter I Karachunski; Basil T Darras; Kate Bushby; Elizabeth C Malkus; Paul T Golumbek; Craig M Zaidman; J Philip Miller; Jerry R Mendell
Journal:  Pediatr Neurol       Date:  2014-02-15       Impact factor: 3.372

10.  Early Neurodevelopmental Findings Predict School Age Cognitive Abilities in Duchenne Muscular Dystrophy: A Longitudinal Study.

Authors:  Daniela Chieffo; Claudia Brogna; Angela Berardinelli; Grazia D'Angelo; Maria Mallardi; Adele D'Amico; Paolo Alfieri; Eugenio Mercuri; Marika Pane
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.